Effect of Apatinib Combined with Oxaliplatin and Raltitrexed in the Treatment of Advanced Colorectal Cancer
Objective To investigate the effect of apatinib combined with RALOX (oxaliplatin+raltitrexed) in the treatment of advanced colorectal cancer. Methods Patients with advanced colorectal cancer who received apatinib com-bined with RALOX (observation group,n=39) or RALOX treatment alone (control group,n=39) in the Department of Gastro-enterology of the 908th Hospital of Joint Logistics Support Force were enrolled in this study. The treatment effects of the two regimens were compared. Results The objective response rate,disease control rate,median progression-free survival time,and overall survival time of patients in the observation group were significantly higher than those in the control group. Addi-tionally,blood CEA and CA199 expression levels were significantly lower after treatment in the observation group compared to the control group (P<0.05). Regarding safety,bone marrow suppression and nausea/vomiting were the most common adverse reactions,mainly classified as grade Ⅰ-Ⅱ. There were no significant differences in the incidence of adverse reactions between the observation and control groups (P>0.05). Conclusions Apatinib combined with RALOX shows better efficacy than RALOX alone in patients with advanced colorectal cancer. Moreover,it does not significantly increase the incidence of adverse effects,making it a recommended second-line treatment option for patients with advanced colorectal cancer.
万方数据
维普
